Skip to content

Public FDA record

Z-0481-2010: Animas ezManager Max Diabetes Management System version 2.0.9

Recall record Z-0481-2010 for Animas Corporation. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0481-2010
Company in FDA record
Animas Corporation
FDA classification date
Dec 3, 2009
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

Printed hard copy of results is not the same as the system screens- carbohydrate to insulin ratio incorrect.

Source facts

Action
Animas issued an Urgent Medical Device Correction letter dated 11/2/09 to the pump user and another letter to the health care professional that prescribed the pump. The letters explain the issue. The patient letter is accompanied with a CD that contains the upgraded software and instructions to follow.
Initiated
2009-11-02
Root cause
Software design
Terminated
2010-10-27
Distribution
Nationwide distribution, and Canada, Cayman Islands, and Denmark.
Recall number
Z-0481-2010
Recall status
Terminated
CDRH record ID
86454
FDA classified
2009-12-03
Recall event number
53748

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗